Full-Time

Senior Product Manager

Downstream Software

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Bachelor's, Master's

Category
Product (1)
Required Skills
Agile
Market Research
Forecasting
Product Management
Tableau
Data Analysis

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Self-directed, nimble, and adaptable with ability to proactively seek advice and feedback when needed
  • Ability to influence cross-functional teams without formal authority. This includes the ability to take the lead in bridging communication between engineering, planning, marketing, sales, and customers. The ability to context-switch between cross-functional groups is key
  • Demonstrated interest in healthcare, hospital operations, and finance
  • Excellent communication and presentation skills, including experience presenting to senior management and customers
  • Strong relationship builder with proven ability to work across multiple disparate parts of an organization to deliver results
  • Excellent teamwork skills with proven ability to collaborate across multiple disciplines to ensure product delivery and success
  • Ability to source information independently and not only identify issues, but proactively propose creative solutions
  • Quantitative mindset, proven ability to investigate open-ended problems and work cross-functionally to implement initiatives
  • Ability to prioritize and work proactively to manage multiple competing deadlines and tasks
  • Strong knowledge of the MS Office product suite. Moderate experience or knowledge with Zoom Whiteboard, Tableau, Agile, and Polarion
  • Ability to work in surgical labs and hospital patient care areas is required
  • Ability to travel up to 30%
  • A BS or BSE in computer science, engineering, mathematics, or a related technical field strongly preferred
  • 5 or more years of professional experience with at least 2 years of experience in medical device product management, program management, project management, product marketing, or a similar discipline
  • Product launch experience
  • Relevant experience in medical devices and/or engineering/technical organizations
  • Ability to travel domestically and internationally
Responsibilities
  • Lead product launch and sustaining efforts across cross-functional technical and commercial stakeholders for next generation software and hardware-based surgical robotics capabilities
  • Propose product feature updates and next-generation capabilities aligned with customer needs and company’s long-term targets
  • Lead cross-functional team to ensure execution of a smooth product rollout process, including product launch, inclusive of: Product Pricing, Product introduction timing, product phase in/phase out, Training Plan
  • Communicate, coordinate, and track project status at various levels of detail, ranging from big picture vision through engineering technical specifications
  • Ensure execution of a smooth product rollout process, primarily in the United States but also global product launches when needed
  • Serve as the single point of contact and liaison to develop, communicate, escalate, and resolve key launch requirements, customer needs, and go-to-market execution plans
  • Understand external customers’ (i.e. clinicians/KOLs, reprocessing teams, hospitals and payors) and internal customers’ (i.e. Field Sales, Customer Support, Field Engineering and Services) needs to identify and develop in-market and product development solutions.
  • Lead Product Management in the SIOP process (Sales, Inventory, Operations Planning) process, working closely with manufacturing and operations, forecasting SKUs
  • Proactively identify product/field risks and lead resolution by developing solutions and execution plans
  • Measure product success by monitoring product adoption and measuring customer satisfaction
  • Monitor and prioritize product quality issues for the product roadmap. Work with cross-functional teams to resolve product issues and critical customer issues
  • Manage downstream partnership efforts with development partners, coordinate key technical workstreams for on-going roadmap development
  • Define appropriate product launch and performance metrics to drive decisions on overall product lifecycle, supplier volume renegotiations, and pricing decisions
  • Identify opportunities for product improvements by analyzing product return data and complaints information
  • Serve as conduit between field and product management team by providing real-time insights from the customer and field-based teams
  • Understand competitive, emerging, and complimentary technology, its impact on Intuitive’s Endoluminal product lines, and go-to-market strategy
  • Conduct qualitative and quantitative market research to inform go-to-market strategy, pricing, and product positioning
Desired Qualifications
  • Masters degree in life science, engineering, or business discipline preferred
  • Experience leading launch and sustaining of multiple software product lines as the single-point-of-contact in a regulated environment
  • Experience in one or more of the following areas preferred: medical software, capital equipment, medical devices, digital health, robotics, regulated product development

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $2.89 billion, up 19% year over year.
  • Management raised 2026 gross margin guidance to 68% to 69%, preserving profitability.
  • Extended instrument use in 2027 should lower hospital costs and accelerate adoption.

What critics are saying

  • FDA recalled 2,781 da Vinci X and Xi units on April 2, 2026.
  • Vdpp sued Intuitive on February 16, 2026, adding fresh patent litigation pressure.
  • J&J cleared Ottava in July 2026, creating a credible general-surgery competitor by 2027.

What makes Intuitive Surgical unique

  • Da Vinci 5 placements reached 246 in Q2 2026, reinforcing platform leadership.
  • Ion procedures grew 36% in Q2 2026, broadening Intuitive beyond da Vinci.
  • Installed bases hit 11,710 da Vinci systems and 1,096 Ion systems by June 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.

Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.

Yahoo Finance
Jul 29th, 2026
Intuitive Surgical stock falls 27% despite 31% operating margin and strong da Vinci system sales

Intuitive Surgical's stock has fallen 27% over the past twelve months, now trading 41% below its two-year high. The robotic surgery pioneer trades at 40.8 times earnings, the highest valuation in its sector. The company maintains a 31% operating margin, outpacing Johnson & Johnson's 27% and Medtronic's 18.8%. Revenue grew 21% over the last twelve months. The firm placed 468 da Vinci systems in the most recent quarter, an 18% increase year-over-year, driven by demand for its new da Vinci 5 platform. However, US procedure growth slowed to 12%, compared to 15% worldwide growth. Management attributed the slowdown to changes in patient coverage and premium dynamics causing treatment deferrals.

Yahoo Finance
Jul 20th, 2026
Intuitive Surgical shares drop 14% despite $2.89B revenue as US procedure growth slows to 12%

Intuitive Surgical reported second-quarter revenue of $2.89 billion, up 19% year-on-year and beating Wall Street estimates. Despite this, shares fell 14.1% to a new 52-week low on Friday. The drop followed concerns about slowing US procedure volumes. Whilst global procedures grew 16%, growth for da Vinci systems in the critical US market moderated to 12%. Management noted that changes in patient coverage may be affecting demand for elective procedures. Paradoxically, capital equipment sales remained strong, with 468 da Vinci systems placed in the quarter, up 18% year-on-year. US placements jumped 24%, driven by the new da Vinci 5 platform. Management also detailed plans for an extended use programme launching in 2027, aimed at reducing costs but potentially impacting high-margin recurring revenue.

Yahoo Finance
Jul 16th, 2026
Intuitive Surgical Q2 revenue climbs 19% to $2.89B as procedures grow 16% globally

Intuitive Surgical reported strong Q2 results, with revenue up 19% year-over-year to $2.89 billion and non-GAAP earnings per share rising 28% to $2.80. Recurring revenue accounted for 85% of total sales. Total procedures increased 16%, driven by 15% growth in da Vinci procedures and 36% growth in Ion procedures. Whilst US growth slowed, international da Vinci procedures rose 20%, expanding across Europe and Asia. The company maintained its 2026 procedure outlook, keeping da Vinci procedure growth guidance at 13.5% to 15.5% whilst raising its non-GAAP gross margin forecast to 68% to 69%. Management highlighted continued demand for newer platforms including da Vinci 5, SP and Ion. The installed base grew to nearly 13,000 systems worldwide.